Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants

Luis Jódar, Jay Butler, George Carlone, Ron Dagan, David Goldblatt, Helena Käyhty, Keith Klugman, Brian Plikaytis, George Siber, Robert Kohberger, Ih Chang, Thomas Cherian

Research output: Contribution to journalArticle

Abstract

The World Health Organization (WHO) is undertaking a series of consultations on serological criteria for the evaluation and licensure of new formulations/combinations or different vaccination schedules of pneumococcal conjugate vaccines. The lack of a definitive serological correlate of protection and the multiplicity of antigens involved, especially since the clinical efficacy of most of the individual serotypes represented in the only licensed vaccine has not been established, are hindering the formulation of criteria for licensure of new formulations or combinations of the vaccine. This report analyses the various options with their relative merits and drawbacks and provides preliminary recommendations as guidance to regulatory agencies in evaluating these vaccines for the purposes of licensure. More detailed recommendations for production and control of pneumococcal conjugate vaccines, including criteria for evaluation for licensure, are currently being drafted.

Original languageEnglish (US)
Pages (from-to)3265-3272
Number of pages8
JournalVaccine
Volume21
Issue number23
DOIs
StatePublished - Jul 4 2003
Externally publishedYes

Fingerprint

Conjugate Vaccines
Pneumococcal Vaccines
Licensure
vaccines
Vaccines
Combined Vaccines
World Health Organization
Appointments and Schedules
Vaccination
Referral and Consultation
serotypes
Antigens
vaccination
antigens

Keywords

  • Conjugate vaccine
  • Correlates of protection
  • Streptococcus pneumoniae

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. / Jódar, Luis; Butler, Jay; Carlone, George; Dagan, Ron; Goldblatt, David; Käyhty, Helena; Klugman, Keith; Plikaytis, Brian; Siber, George; Kohberger, Robert; Chang, Ih; Cherian, Thomas.

In: Vaccine, Vol. 21, No. 23, 04.07.2003, p. 3265-3272.

Research output: Contribution to journalArticle

Jódar, L, Butler, J, Carlone, G, Dagan, R, Goldblatt, D, Käyhty, H, Klugman, K, Plikaytis, B, Siber, G, Kohberger, R, Chang, I & Cherian, T 2003, 'Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants', Vaccine, vol. 21, no. 23, pp. 3265-3272. https://doi.org/10.1016/S0264-410X(03)00230-5
Jódar, Luis ; Butler, Jay ; Carlone, George ; Dagan, Ron ; Goldblatt, David ; Käyhty, Helena ; Klugman, Keith ; Plikaytis, Brian ; Siber, George ; Kohberger, Robert ; Chang, Ih ; Cherian, Thomas. / Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. In: Vaccine. 2003 ; Vol. 21, No. 23. pp. 3265-3272.
@article{86a2766901544ac791e2ae926849d16c,
title = "Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants",
abstract = "The World Health Organization (WHO) is undertaking a series of consultations on serological criteria for the evaluation and licensure of new formulations/combinations or different vaccination schedules of pneumococcal conjugate vaccines. The lack of a definitive serological correlate of protection and the multiplicity of antigens involved, especially since the clinical efficacy of most of the individual serotypes represented in the only licensed vaccine has not been established, are hindering the formulation of criteria for licensure of new formulations or combinations of the vaccine. This report analyses the various options with their relative merits and drawbacks and provides preliminary recommendations as guidance to regulatory agencies in evaluating these vaccines for the purposes of licensure. More detailed recommendations for production and control of pneumococcal conjugate vaccines, including criteria for evaluation for licensure, are currently being drafted.",
keywords = "Conjugate vaccine, Correlates of protection, Streptococcus pneumoniae",
author = "Luis J{\'o}dar and Jay Butler and George Carlone and Ron Dagan and David Goldblatt and Helena K{\"a}yhty and Keith Klugman and Brian Plikaytis and George Siber and Robert Kohberger and Ih Chang and Thomas Cherian",
year = "2003",
month = "7",
day = "4",
doi = "10.1016/S0264-410X(03)00230-5",
language = "English (US)",
volume = "21",
pages = "3265--3272",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "23",

}

TY - JOUR

T1 - Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants

AU - Jódar, Luis

AU - Butler, Jay

AU - Carlone, George

AU - Dagan, Ron

AU - Goldblatt, David

AU - Käyhty, Helena

AU - Klugman, Keith

AU - Plikaytis, Brian

AU - Siber, George

AU - Kohberger, Robert

AU - Chang, Ih

AU - Cherian, Thomas

PY - 2003/7/4

Y1 - 2003/7/4

N2 - The World Health Organization (WHO) is undertaking a series of consultations on serological criteria for the evaluation and licensure of new formulations/combinations or different vaccination schedules of pneumococcal conjugate vaccines. The lack of a definitive serological correlate of protection and the multiplicity of antigens involved, especially since the clinical efficacy of most of the individual serotypes represented in the only licensed vaccine has not been established, are hindering the formulation of criteria for licensure of new formulations or combinations of the vaccine. This report analyses the various options with their relative merits and drawbacks and provides preliminary recommendations as guidance to regulatory agencies in evaluating these vaccines for the purposes of licensure. More detailed recommendations for production and control of pneumococcal conjugate vaccines, including criteria for evaluation for licensure, are currently being drafted.

AB - The World Health Organization (WHO) is undertaking a series of consultations on serological criteria for the evaluation and licensure of new formulations/combinations or different vaccination schedules of pneumococcal conjugate vaccines. The lack of a definitive serological correlate of protection and the multiplicity of antigens involved, especially since the clinical efficacy of most of the individual serotypes represented in the only licensed vaccine has not been established, are hindering the formulation of criteria for licensure of new formulations or combinations of the vaccine. This report analyses the various options with their relative merits and drawbacks and provides preliminary recommendations as guidance to regulatory agencies in evaluating these vaccines for the purposes of licensure. More detailed recommendations for production and control of pneumococcal conjugate vaccines, including criteria for evaluation for licensure, are currently being drafted.

KW - Conjugate vaccine

KW - Correlates of protection

KW - Streptococcus pneumoniae

UR - http://www.scopus.com/inward/record.url?scp=12444288124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12444288124&partnerID=8YFLogxK

U2 - 10.1016/S0264-410X(03)00230-5

DO - 10.1016/S0264-410X(03)00230-5

M3 - Article

VL - 21

SP - 3265

EP - 3272

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 23

ER -